PRFX logo

PRF TECHNOLOGIES LTD

PRFXNASDAQ
🏆 #5356 by market capUS Equity
$0.79▲ $0.06 (+8.45%)
After hours · at close
🔔
Track PRFX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 8.4%
7d▲ 3.8%
14d▼ 5.3%
30d▼ 18.7%
ytd▼ 75.4%
1y▼ 87.8%
🏦Market Cap
$63,636
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
-307.6%
Thin
💵FCF Margin
-18684.8%
Thin
⚖️P/S Ratio
1.5x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$0.79 – $0.79
52-Week Range
$0.69 – $7.95
Volume (shares)
100
Avg Volume (shares)
—
Shares Outstanding
80,532
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$17,000
Last Q Revenue
$7,000
P/E Ratio
-0.1
P/S Ratio
1.5x
EPS (TTM)
$-7.15
Dividend Yield
0.00%
Dilution (1yr)
+1000.9%
PRFX logo

PRF TECHNOLOGIES LTD

PRFX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$17K▲ +0.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-4864.7%▼ −5992.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$5M▼ −66.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$4M▼ −68.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
648K▲ +1000.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$3M▼ −$1M YoY
StockOtter · stockotter.space

About PRF TECHNOLOGIES LTD

PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.